Business Description
CRISPR Therapeutics AG
ISIN : CH0334081137
Share Class Description:
CRSP: Ordinary SharesDescription
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.46 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.48 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 7.35 | |||||
| Beneish M-Score | -5.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -66.8 | |||||
| 3-Year Book Growth Rate | -10.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 136.56 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.69 | |||||
| 9-Day RSI | 78.58 | |||||
| 14-Day RSI | 73.91 | |||||
| 3-1 Month Momentum % | 9.51 | |||||
| 6-1 Month Momentum % | -7.8 | |||||
| 12-1 Month Momentum % | -32.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.64 | |||||
| Quick Ratio | 15.64 | |||||
| Cash Ratio | 15.53 | |||||
| Days Sales Outstanding | 1173.21 | |||||
| Days Payable | 41.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.7 | |||||
| Shareholder Yield % | -0.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -245.12 | |||||
| Operating Margin % | -1355.43 | |||||
| Net Margin % | -1101.88 | |||||
| EBITDA Margin % | -1300.69 | |||||
| FCF Margin % | -879.6 | |||||
| ROE % | -19.75 | |||||
| ROA % | -16.85 | |||||
| ROIC % | -141.51 | |||||
| 3-Year ROIIC % | 7490.96 | |||||
| ROC (Joel Greenblatt) % | -166.79 | |||||
| ROCE % | -21.76 | |||||
| Years of Profitability over Past 10-Year | 2 | |||||
| Moat score | 6 | |||||
| Tariff score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 126.51 | |||||
| PB Ratio | 2.44 | |||||
| Price-to-Tangible-Book | 2.44 | |||||
| EV-to-EBIT | -5.38 | |||||
| EV-to-Forward-EBIT | -7.52 | |||||
| EV-to-EBITDA | -5.61 | |||||
| EV-to-Forward-EBITDA | -7.57 | |||||
| EV-to-Revenue | 72.96 | |||||
| EV-to-Forward-Revenue | 108.73 | |||||
| EV-to-FCF | -8.29 | |||||
| Price-to-GF-Value | 4.3 | |||||
| Price-to-Projected-FCF | 14.08 | |||||
| Price-to-Net-Current-Asset-Value | 2.92 | |||||
| Price-to-Net-Cash | 2.94 | |||||
| Earnings Yield (Greenblatt) % | -18.59 | |||||
| FCF Yield % | -6.9 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers